Microbot Medical Outlined Robotic Expansion Strategy

The company has secured its first customer in California as it scales sales of its FDA-cleared surgical robotic system.

Updated on Sept. 25, 2026 in Robotics

Microbot Medical Outlined Robotic Expansion Strategy

Live Poll

Do you trust that new medical robotics technologies are being safely and reliably integrated into hospitals?

Microbot Medical shared its commercial growth strategy for its LIBERTY System during an analyst meeting in New York City. The medical robotics firm has also expanded its sales operations into North Carolina and signed its first customer in California.

Why it matters

The company is working to accelerate the adoption of its remotely operated robotic technology across major multi-hospital healthcare systems. By scaling its sales force and manufacturing capacity, the firm aims to establish a broader footprint in the peripheral endovascular market.

The LIBERTY System is an FDA-cleared, single-use, remotely operated robotic platform designed for peripheral endovascular procedures. The firm has added a second manufacturing line to boost efficiency and expects the Value Analysis Committee process to take 4-6 months.

The players

Microbot Medical

This medical device company is based in Hingham, Massachusetts, and focuses on developing robotic surgical technologies.

The details

Microbot Medical is scaling its human capital, having recently added three Area Sales Managers and one Regional Sales Director. These hires support the strategic push to integrate the LIBERTY System into hospital workflows via formal Value Analysis Committee reviews.

September 24, 2026: The company held an analyst meeting in New York City.
End of 2026: The company targets having 12 total sales territories.
Late Q4 2026 or early Q1 2027: The firm expects to receive CE mark approval.
2027: The company expects to achieve positive gross margins.

The Tech Race

The push to scale the LIBERTY System follows a pattern of specialized robotic platforms seeking to capture market share from traditional manual endovascular procedures. This transition reflects a broader industry shift toward automating repetitive surgical tasks to improve clinical precision and hospital throughput.

Healthcare providers in regions targeted by the company's expansion can expect increased access to remote robotic assistance for endovascular treatments. Patients at these systems may see changes to surgical protocols as hospitals adopt these single-use robotic technologies.

The takeaway

Microbot Medical is shifting its focus toward commercial scaling and territory expansion ahead of anticipated international regulatory milestones. Investors and healthcare stakeholders should monitor the pace of new customer acquisitions as the firm moves toward its goal of positive gross margins in 2027.